Beijing Airdoc Technology Co (HKSE:02251) Altman Z2-Score: 16.21 (As of Sep. 03, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02251 Beijing Airdoc Technology Co Ltd HKSE:02251
64 GF Score
Price HK$7.90
GF Value HK$15.18
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Beijing Airdoc Technology Co Altman Z2-Score?

Beijing Airdoc Technology Co HKSE:02251 64 Altman Z2-Score is 16.21 as of Sep. 03, 2026, which is at its 10-year median of 16.21. GuruFocus rates HKSE:02251 with a GF Score™ of 64/100 and a GF Value™ of HK$15.18 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 624 Healthcare Providers & Services companies, Beijing Airdoc Technology Co ranks better than 97.76% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Beijing Airdoc Technology Co has a Altman Z2-Score of 16.21, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Beijing Airdoc Technology Co's Altman Z2-Score or its related term are showing as below:

HKSE:02251' s Altman Z2-Score Range Over the Past 10 Years
Min: -7.34   Med: 16.21   Max: 31.4
Current: 16.21

During the past 7 years, Beijing Airdoc Technology Co's highest Altman Z2-Score was 31.40. The lowest was -7.34. And the median was 16.21.


Beijing Airdoc Technology Co  (HKSE:02251) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Beijing Airdoc Technology Co Altman Z2-Score Related Terms


Beijing Airdoc Technology Co Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Beijing Airdoc Technology Co's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Airdoc Technology Co Altman Z2-Score Chart

Beijing Airdoc Technology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial 31.40 30.23 15.78 10.49 16.21

Beijing Airdoc Technology Co Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.78 0.00 10.49 0.00 16.21

HKSE:02251 vs VEEV, BTSG, TEM: Altman Z2-Score Comparison

For the Health Information Services subindustry, Beijing Airdoc Technology Co's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Airdoc Technology Co Altman Z2-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Beijing Airdoc Technology Co's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Beijing Airdoc Technology Co's Altman Z2-Score falls into.


HKSE:02251
64GF Score
Beijing Airdoc Technology Co Ltd HKSE:02251
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Airdoc Technology Co Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Beijing Airdoc Technology Co's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.5473+3.26*-0.5789+6.72*-0.0208+1.05*13.9457
=16.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2025:
Total Assets was HK$1,447.5 Mil.
Total Current Assets was HK$875.4 Mil.
Total Current Liabilities was HK$83.1 Mil.
Retained Earnings was HK$-838.0 Mil.
Pre-Tax Income was HK$-30.5 Mil.
Interest Expense was HK$-0.4 Mil.
Total Liabilities was HK$97.3 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(875.383 - 83.146)/1447.545
=0.5473

X2=Retained Earnings/Total Assets
=-837.964/1447.545
=-0.5789

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-30.535 - -0.381)/1447.545
=-0.0208

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(1356.306 - 0)/97.256
=13.9457

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Beijing Airdoc Technology Co has a Altman Z2-Score of 16.21 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 16.21 mean?
Beijing Airdoc Technology Co (HKSE:02251) has a Altman Z2-Score of 16.21 as of Sep. 03, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Beijing Airdoc Technology Co and its competitors. This is near median its historical median of 16.21. According to the industry distribution chart, Beijing Airdoc Technology Co ranks #14 out of 624 companies in the Healthcare Providers & Services industry, placing it in the top 2.2%.
Is Beijing Airdoc Technology Co's Altman Z2-Score too high?
Beijing Airdoc Technology Co's current Altman Z2-Score of 16.21 is near median its 10-year median of 16.21. The Healthcare Providers & Services industry median Altman Z2-Score is 2.07. Beijing Airdoc Technology Co's value of 16.21 is 685% above this industry median. Based on the distribution chart, Beijing Airdoc Technology Co ranks #14 out of 624 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Beijing Airdoc Technology Co has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Airdoc Technology Co's Altman Z2-Score compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Beijing Airdoc Technology Co ranks #14 out of 624 companies for Altman Z2-Score. This places Beijing Airdoc Technology Co in the top 2% of its industry — outperforming the majority of peers. The industry median Altman Z2-Score is 2.07. Beijing Airdoc Technology Co's value of 16.21 is 685% above this benchmark. While the company's 10-year median is 16.21 vs. the industry median of 2.07, Beijing Airdoc Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Healthcare Providers & Services company?
The median Altman Z2-Score among Healthcare Providers & Services companies is 2.07, based on 624 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Airdoc Technology Co's current Altman Z2-Score of 16.21 is 685% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Beijing Airdoc Technology Co and its competitors. For the Healthcare Providers & Services industry, the median Altman Z2-Score is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Airdoc Technology Co's current Altman Z2-Score is 16.21, which is near median its own 10-year median of 16.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Airdoc Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Airdoc Technology Co (HKSE:02251) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$15.18, compared to a current price of HK$7.90 — trading 48% below its estimated fair value. The current Altman Z2-Score is 16.21, which is near median its 10-year median of 16.21 and 685% above the Healthcare Providers & Services industry median of 2.07. Beijing Airdoc Technology Co's overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Beijing Airdoc Technology Co (HKSE:02251), the current Altman Z2-Score is 16.21 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beijing Airdoc Technology Co (HKSE:02251) Overvalued in 2026?

Based on GuruFocus' analysis, Beijing Airdoc Technology Co stock appears to be undervalued. The current stock price of HK$7.90 is trading 48% below its estimated GF Value™ of HK$15.18. GuruFocus considers Beijing Airdoc Technology Co to be Significantly Undervalued.

Key valuation signals for HKSE:02251:

  • Altman Z2-Score: 16.21 (near median its 10-year median of 16.21)
  • GF Value™: HK$15.18 vs. price of HK$7.90 (48% below fair value)
  • GF Score™: 64/100 with 4 warning signs
  • Industry Position: 685% above the Healthcare Providers & Services median (#14 of 624)

No single metric tells the full story. See the HKSE:02251 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Beijing Airdoc Technology Co Business Description

Address West Third Ring North Road, Room 21, 4th Floor, Building 2, A2 Yard, Haidian District, Beijing, CHN, 100089
Beijing Airdoc Technology Co Ltd provides AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions in China. Leveraging retinal imaging, multimodal data analyses, and AI deep learning algorithms, the company's solution differs from traditional chronic disease early detection and diagnosis, enabling non-invasive, accurate, fast, effective, and scalable detection and diagnosis of chronic diseases in both medical institutions and consumer healthcare providers. The Company derives revenue from the provision of AI-based software solutions, sales of hardware devices, and other services. Geographically, the company generates the majority of its revenue from Mainland China.
64GF Score

Get the complete analysis for HKSE:02251

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$7.90
Price
HK$15.18
GF Value